Kyle Munz

The National Institutes of Health (NIH) has cancelled crucial funding for the nationwide Diabetes Prevention Program (DPP). For the last 30 years, the DPP gathered valuable data tracking patients with diabetes and prediabetes. Although the reasoning behind the move remains […]

Chronic inflammatory demyelinating polyneuropathy (CIDP) imposes a considerable burden on health care systems, caregivers, and patients alike. From rising financial costs to disruptions in employment and daily life, the aftermath of a CIDP diagnosis can contribute to a myriad of

At present, the FDA has approved a single gene therapy for patients with Duchenne muscular dystrophy (DMD): delandistrogene moxeparvovec (Elevidys; Sarepta Therapeutics). This therapy may be delivered through the use of an adeno-associated virus (AAV) vector. However, as trials with

Adeno-associated virus (AAV)–mediated gene therapy has particularly transformed the treatment landscape of Duchenne muscular dystrophy (DMD); however, clinical approaches with this intervention vary based on a number of factors. Here, Barry Byrne, MD, PhD, pediatric cardiologist, director, Powell Gene Therapy

The upcoming Greater Philadelphia Business Coalition on Health (GPBCH) Employer Symposia: The Heart & Other Muscles to aims to provide practical, actionable insights for managing the challenges brought about by cardiovascular and musculoskeletal (MSK) disease. This meeting, Tom Belmont, CAP,

A combination therapy of atezolizumab (tecentriq) with rituximab (Rituxan), gemcitabine (gemzar), and oxaliplatin (eloxatin; GemOx; R-GemOx+Atezo) has demonstrated favorable safety and efficacy in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). These findings, published in Haematologica, indicated that those

Muscular Dystrophy Association (MDA), established in 1950, and is set to convene for its 75th meeting. Looking ahead to this year’s event, Sharon Hesterlee, PhD, chief research officer at MDA, praised the breadth of research to be presented. With presentations,

A lipidomic analysis identified higher concentrations of deoxycholic acid, triacylglycerols (TAG), ceramides, and certain phospholipids in patients with metabolic dysfunction–associated steatohepatitis (MASH). These insights, published in PLoS One, demonstrated how a lipid metabolite panel could serve as a noninvasive and

In part 1 of this interview, Antoine Keller, MD, FACC, FACS, cardiothoracic surgeon, Ochsner Lafayette General Hospital, and founder of HeartSense discussed his experiences as a cardiac surgeon that ultimately led to the organization’s founding. Of particular concern to him

One of the prominent gaps in hematologic research, argues Sabarish Ayyappan, MD, City of Hope Cancer Center, Atlanta, is the lack of cost-effectiveness studies. Efforts to unveil cost-related outcomes and compile more data in this area can ultimately alleviate health